The AML Global Portal were delighted to speak to Catherine Smith, UCSF Medical Center, San Francisco, US , during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Catherine Smith: How will the use of FLT3 inhibitors evolve in the future?
She provided her expert opinion outlining the challenge of resistance development, both on-target and off-target and how the field is currently trying to overcome them with drug combination regimens. She provided arguments for a sequential use of different treatment modalities in order to better address the heterogeneity of AML at diagnosis and relapse.
